Education
About Us
Working with TipRanks
Follow Us
NeoGenomics Inc. (NEO)
:NEO
NEO Stock Chart & Stats
$10.40
$0.52(2.83%)
At close: 4:00 PM EST
$10.40
$0.52(2.83%)
Day’s Range― - ―
52-Week Range$4.72 - $19.12
Previous CloseN/A
Volume108.49K
Average Volume (3M)4.53M
Market Cap
$1.35B
Enterprise Value$1.24B
Total Cash (Recent Filing)$164.12M
Total Debt (Recent Filing)$410.31M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Feb 25, 2026EPS Estimate
0.04Last Dividend Ex-Date
Dec 17, 2020Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding129,387,800
10 Day Avg. Volume4,140,149
30 Day Avg. Volume4,526,006
Financial Highlights & Ratios
PEG Ratio0.46
Price to Book (P/B)0.46
Price to Sales (P/S)0.63
P/FCF Ratio-12.26
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue1.75
Enterprise Value/Gross Profit4.02
Enterprise Value/Ebitda-36.68
Forecast
1Y Price Target
$13.14Price Target Upside26.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)0.1
Revenue Forecast (FY)$725.03M
Bulls Say, Bears Say
Bulls Say
EarningsNeoGenomics reported better than expected 3Q revenue of $187.8 million, up 11.9%.
Legal DevelopmentsRaDaR recently secured a favorable court ruling against Natera, effectively removing a key legal overhang and paving the way for clinical launch.
Revenue GrowthNext-Generation Sequencing revenue continues to drive growth and now accounts for 33% of total clinical revenue.
Bears Say
Growth SustainabilityQuestions remain on the sustainability of growth rate and competitive position in the liquid biopsy/NGS market.
Management CredibilityManagement needs to reestablish its credibility before any upward revision beyond the consensus is warranted.
Non-Clinical RevenueRevenue from Non-clinical sources continues to languish due to the discontinuation of RaDaR 1.0 and macro pressure on the biopharma testing market.
NeoGenomics News
NEO FAQ
What was NeoGenomics Inc.’s price range in the past 12 months?
NeoGenomics Inc. lowest stock price was $4.72 and its highest was $19.11 in the past 12 months.
What is NeoGenomics Inc.’s market cap?
NeoGenomics Inc.’s market cap is $1.35B.
When is NeoGenomics Inc.’s upcoming earnings report date?
NeoGenomics Inc.’s upcoming earnings report date is Feb 25, 2026 which is in 109 days.
How were NeoGenomics Inc.’s earnings last quarter?
NeoGenomics Inc. released its earnings results on Oct 28, 2025. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of $0.021 by $0.009.
Is NeoGenomics Inc. overvalued?
According to Wall Street analysts NeoGenomics Inc.’s price is currently Undervalued.
Does NeoGenomics Inc. pay dividends?
NeoGenomics Inc. pays a Notavailable dividend of $0.4 which represents an annual dividend yield of N/A. See more information on NeoGenomics Inc. dividends here
What is NeoGenomics Inc.’s EPS estimate?
NeoGenomics Inc.’s EPS estimate is 0.04.
How many shares outstanding does NeoGenomics Inc. have?
NeoGenomics Inc. has 129,387,800 shares outstanding.
What happened to NeoGenomics Inc.’s price movement after its last earnings report?
NeoGenomics Inc. reported an EPS of $0.03 in its last earnings report, beating expectations of $0.021. Following the earnings report the stock price went down -2.362%.
Which hedge fund is a major shareholder of NeoGenomics Inc.?
Currently, no hedge funds are holding shares in NEO
NeoGenomics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.14 (26.35% Upside)
$13.14 (26.35% Upside)
Blogger Sentiment
Neutral
NEO Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 2.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-32.72%
12-Months-Change
Fundamentals
Return on Equity
-12.99%
Trailing 12-Months
Asset Growth
-16.23%
Trailing 12-Months
Company Description
NeoGenomics Inc.
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
NEO Company Deck
NEO Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a strong performance in the clinical segment, driven by volume and revenue growth, successful acquisitions, and favorable legal outcomes. However, challenges remain in nonclinical revenue, particularly in pharma, which are expected to persist into 2026.View all NEO earnings summariesNEO Stock 12 Month Forecast
Average Price Target
$13.14
▲(26.35% Upside)
Technical Analysis
Ownership Overview
1.23% Insiders
30.08% Mutual Funds
0.16% Other Institutional Investors
44.02% Public Companies and
Individual Investors